Genertec Universal Medical Group Company Limited

SEHK:2666 Stock Report

Market Cap: HK$9.0b

Genertec Universal Medical Group Future Growth

Future criteria checks 1/6

Genertec Universal Medical Group is forecast to grow earnings and revenue by 6.8% and 7.5% per annum respectively. EPS is expected to grow by 5.8% per annum. Return on equity is forecast to be 11.8% in 3 years.

Key information

6.8%

Earnings growth rate

5.8%

EPS growth rate

Diversified Financial earnings growth25.4%
Revenue growth rate7.5%
Future return on equity11.8%
Analyst coverage

Low

Last updated13 Nov 2024

Recent future growth updates

Recent updates

Earnings Working Against Genertec Universal Medical Group Company Limited's (HKG:2666) Share Price

Oct 09
Earnings Working Against Genertec Universal Medical Group Company Limited's (HKG:2666) Share Price

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

May 22
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking

May 10
Genertec Universal Medical Group Company Limited's (HKG:2666) Price Is Right But Growth Is Lacking

Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E

Feb 05
Why Investors Shouldn't Be Surprised By Genertec Universal Medical Group Company Limited's (HKG:2666) Low P/E

Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34

Jun 08
Genertec Universal Medical Group (HKG:2666) Is Reducing Its Dividend To CN¥0.34

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Jun 08
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 31
Genertec Universal Medical Group's (HKG:2666) Shareholders Will Receive A Bigger Dividend Than Last Year

Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?

Aug 20
Should You Be Adding Genertec Universal Medical Group (HKG:2666) To Your Watchlist Today?

Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching

Apr 19
Here's Why We Think Genertec Universal Medical Group (HKG:2666) Is Well Worth Watching

Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return

Mar 10
Shareholders Of Genertec Universal Medical Group (HKG:2666) Must Be Happy With Their 34% Return

Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?

Feb 19
Is Genertec Universal Medical Group Company Limited (HKG:2666) Trading At A 48% Discount?

Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?

Feb 01
Did Genertec Universal Medical Group Company Limited (HKG:2666) Insiders Buy Up More Shares?

The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?

Jan 11
The Case For Genertec Universal Medical Group Company Limited (HKG:2666): Could It Be A Nice Addition To Your Dividend Portfolio?

What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?

Dec 21
What Kind Of Investors Own Most Of Genertec Universal Medical Group Company Limited (HKG:2666)?

Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years

Nov 30
Reflecting on Genertec Universal Medical Group's (HKG:2666) Share Price Returns Over The Last Three Years

Earnings and Revenue Growth Forecasts

SEHK:2666 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202615,9282,4573,4904,5492
12/31/202515,1332,3222,6193,5973
12/31/202414,0492,1972,3463,3243
6/30/202413,2032,0615,2246,385N/A
3/31/202413,3112,0414,6615,690N/A
12/31/202313,4192,0214,0974,994N/A
9/30/202313,1611,9601,6232,479N/A
6/30/202312,7971,896-823-12N/A
3/31/202312,2641,8922961,010N/A
12/31/202211,7301,8881,4142,032N/A
9/30/202211,0181,8821,1691,682N/A
6/30/202210,3051,8759231,333N/A
3/31/20229,9361,855-431-34N/A
12/31/20219,5671,835-1,786-1,401N/A
9/30/20219,3711,870-3,883-3,520N/A
6/30/20219,1751,904-5,980-5,640N/A
3/31/20218,7091,776-3,676-3,306N/A
12/31/20208,2431,648-1,373-972N/A
9/30/20207,8431,5598481,212N/A
6/30/20207,4441,4703,0703,397N/A
3/31/20207,0951,479519786N/A
12/31/20196,7471,489-2,032-1,824N/A
9/30/20196,0711,459-4,512-4,367N/A
6/30/20195,3951,429-6,991-6,909N/A
3/31/20194,8451,390-6,369-6,319N/A
12/31/20184,2951,352-5,746-5,729N/A
9/30/20184,0801,329-6,215-6,198N/A
6/30/20183,8651,305-6,683-6,667N/A
3/31/20183,6451,227N/A-5,870N/A
12/31/20173,4241,149N/A-5,072N/A
9/30/20173,2671,105N/A-4,400N/A
6/30/20173,1111,062N/A-3,729N/A
3/31/20172,910967N/A-3,055N/A
12/31/20162,709872N/A-2,382N/A
9/30/20162,587825N/A-2,577N/A
6/30/20162,464778N/A-2,773N/A
3/31/20162,330718N/A-3,613N/A
12/31/20152,195659N/A-4,452N/A
9/30/20152,031605N/A-4,702N/A
6/30/20151,866551N/A-4,951N/A
3/31/20151,711504N/A-4,531N/A
12/31/20141,557457N/A-4,111N/A
12/31/2013984313N/A-4,119N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 2666's forecast earnings growth (6.8% per year) is above the savings rate (2.3%).

Earnings vs Market: 2666's earnings (6.8% per year) are forecast to grow slower than the Hong Kong market (11.6% per year).

High Growth Earnings: 2666's earnings are forecast to grow, but not significantly.

Revenue vs Market: 2666's revenue (7.5% per year) is forecast to grow slower than the Hong Kong market (7.8% per year).

High Growth Revenue: 2666's revenue (7.5% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 2666's Return on Equity is forecast to be low in 3 years time (11.8%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 10:01
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Genertec Universal Medical Group Company Limited is covered by 16 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBOCOM International Securities Limited
Yolanda YinCGS International
Yolanda YinChina Galaxy International Securities (Hong Kong)